Skip to main content
Admissions guidance, study banks, and career tools — get started on Shalyam
Research News

Alzheimer's Drugs May Not Work and Could Raise Brain Risks

Mayur Tembhare
  1. Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

  2. Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

  3. Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

  4. Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

Alzheimer's Drugs May Not Work and Could Raise Brain Risks

Topic: Research News

Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

A recent study looked at a type of drug designed to remove amyloid beta proteins from the brains of people with Alzheimer's disease. This protein builds up in the brain years before symptoms appear. The researchers combined results from 17 clinical trials involving over 20,000 participants.

The study found that these drugs do not make a meaningful difference for patients. In fact, the effects were very small and below the level considered important for patients. Lead author Francesco Nonino said,

Implications

Scientists studied Alzheimer's drugs that target amyloid beta proteins. They found that these drugs do not help patients much and might increase brain swelling and bleeding.

Source: https://www.sciencedaily.com/releases/2026/05/260502233915.htm

Journal reference:

  1. Francesco Nonino, Silvia Minozzi, Luisa Sambati, Cinzia Del Giovane, Elisa Baldin, Maria Chiara Bassi, Claudia De Santis, Marien Gonzalez-Lorenzo, Luca Vignatelli, Graziella Filippini, Edo Richard. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews, 2026; 2026 (4) DOI: 10.1002/14651858.CD016297

Leave a comment

← All research

Get Exclusive Insights with Every Issue

Join Shalyam Newsletter

Stay ahead in education, research, and innovation—straight to your inbox.